BioSpace News Archive

XOMA Corporation, the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

Zevra Therapeutics, Inc., a rare disease therapeutics company, announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease.

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, announced financial results for the first quarter ended March 31, 2024 and provided an update on its business.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Trevi Therapeutics, Inc. today announced that senior management will be attending investor, business development and medical conferences in May and June.

Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2024.

Apnimed announced the early completion of enrollment in its LunAIRo Phase 3 study designed to examine the efficacy and safety of its lead candidate AD109 compared to placebo at six months and one year.

Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024.

Vera Therapeutics, Inc. reported its business highlights and financial results for the first quarter ended March 31, 2024.